Saniona (SANION) investor relations material

Company overview and financials

• Focuses on neurological and psychiatric diseases with a partnership-driven business model.

• Market cap of 1.6 BSEK ($167M) as of August 2026; share price SEK 11.44 ($1.19 USD).

• Strong financial position with 486 MSEK ($51M) in cash and 165 MSEK ($17.5M) in near-term milestones.

• Revenue and profit before tax for 2024-2025 driven by partnerships with Acadia and Jazz.

Pipeline highlights: SAN2668 for paediatric epilepsy (DEE)

• SAN2668 targets GABAα2/α3 for developmental and epileptic encephalopathies, aiming for best-in-class efficacy and improved tolerability.

• Designed to minimize adverse effects associated with benzodiazepines by balanced α1 engagement.

• Demonstrates superior seizure control and no motor impairment in preclinical models.

• Suppresses spike-wave discharges and improves cognition and behavior in genetic DEE models.

• Multiple clinical catalysts expected through 2029, with Phase 1 and PoC studies planned.

Pipeline highlights: SAN2465 for MDD/TRD

• SAN2465 is an oral, α5-selective NAM designed for rapid antidepressant effect and cognitive benefit.

• Addresses unmet need for fast-acting, at-home therapy for major depressive disorder and treatment-resistant depression.

• Shares ketamine’s rapid-onset pathway but with a differentiated safety profile and no need for in-clinic monitoring.

• Produces rapid improvements in anhedonia, anxiety, and cognition in preclinical models.

• Phase 1 to establish biomarkers and enable Phase 2 in TRD, with results expected by end of 2027.